Medicine and Dentistry
Therapeutic Procedure
100%
Patient
100%
Non Small Cell Lung Cancer
100%
Survival
100%
Tyrosine-Kinase Inhibitor
95%
Epidermal Growth Factor Receptor
50%
Oncogene
50%
Brain Metastasis
30%
Overall Survival
20%
Progression Free Survival
20%
Diagnosis
20%
Inpatient
14%
Cancer Staging
13%
Death
12%
Follow up
10%
Systemic Therapy
10%
Cancer Registry
9%
Female
8%
Gender
8%
Patient Population
5%
Gene
5%
Tenidap
5%
Kaplan Meier Method
5%
Magnetic Resonance Imaging
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Survival
100%
Protein Tyrosine Kinase Inhibitor
100%
Epidermal Growth Factor Receptor
50%
Brain Metastasis
33%
Progression Free Survival
22%
Overall Survival
22%
Cancer Staging
13%
Death
12%
Systemic Treatment
11%
Cancer Registry
9%
Tenidap
5%
Chemotherapy
5%
Nursing and Health Professions
Survival
50%
Non Small Cell Lung Cancer
50%
Protein Tyrosine Kinase Inhibitor
45%
Brain Metastasis
30%
Diagnosis
20%
Overall Survival
20%
Progression Free Survival
20%
Follow up
10%
Systemic Therapy
10%
Kaplan Meier Method
5%
Cancer Staging
5%
Cancer Registry
5%
Chemotherapy
5%
Nuclear Magnetic Resonance Imaging
5%
Tenidap
5%
Standard
5%